ClinicalTrials.gg
RecruitingNCT07622108Updated Oct 14, 2026

Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

A Phase 3 interventional study of MHB018A and MHB018A placebo in Thyroid Eye Disease, TED, sponsored by Minghui Pharmaceutical (Hangzhou) Ltd. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Minghui Pharmaceutical (Hangzhou) Ltd (part of Minghui Pharmaceutical) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 14, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Planned enrollment
24th of 47
84 · median 84
Started
2026
with 8 others
Phase 3
21 of 53
3 open now
Primary completion
2028-07
later than 13 of 17 live
Registered
49th of 53
by date
Lead sponsor
2 of 53
Minghui Pharmaceutical (Hangzhou) Ltd

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 24th largest by planned enrollment of the 47 interventional ones that give a count, is one of 9 that started in 2026, is one of 21 in phase 3, reaches primary completion later than 13 of the 17 other live ones, and was the 49th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.

Read the detailed description

The investigational drug, MHB018A, is a monoclonal antibody that inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R may help to reduce the inflammation and associated tissue swelling that occurs in patients with thyroid eye disease (TED). The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with active moderate-to-severe TED.

03

Conditions studied

  • Thyroid Eye Disease, TED

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 14, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Body weight ≤ 120 kg.
  2. Clinical diagnosis of active TED with documented medical evidence of symptoms and signs in the study eye occurring within the 12 months prior to study screening. The CAS of the study eye at screening and baseline must be ≥ 3 points (7-point scale).
  3. Clinical diagnosis of moderate-to-severe TED at screening and baseline.
  4. Do not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study.
  5. Diabetic participants must have well-controlled stable disease.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have: a compressive optic neuropathy of TED that requires timely and effective medical intervention; corneal abnormalities that may compromise the assessment of efficacy; previously received orbital radiotherapy or ophthalmic surgery for TED.
  2. Participants who received: oral or intravenous or corticosteroid eye drops/ointments for TED within 4 weeks prior to the first dose of study intervention; periorbital or intraorbital steroid within 3 months before the first dose of study intervention; oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to the first dose of study intervention, excluding local use (topical, nasal, inhalation); other agent, including treatment with any anti-CD20 monoclonal antibody (eg, rituximab) within 6 months before the first dose of study intervention; or treatment with any other immunosuppressive agent (eg, tocilizumab) within 3 months before the first dose of study intervention; or receipt of periorbital or intraorbital administration of any such immunosuppressive agent at any time (eye drops or ointments for dry eye are permitted); previous treatment targeting IGF-1R.
  3. Have received: selenium and vitamin D supplements (as single agents) within 2 weeks prior to the first dose of study intervention or during the study (non-prescription multivitamin containing them is permitted), radioactive iodine treatment within 8 weeks prior to the first dose of study intervention; periocular botulinum toxin injection within 12 months prior to the first dose of study intervention; an agent for any condition (including TED) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  4. Identified pre-existing ophthalmic disease that, would preclude study participation or complicate interpretation of the study results.
  5. Any within 5 years prior to the first dose of study intervention, with the exception of successfully treated malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin or carcinoma of the thyroid.
  6. Acute cardiovascular disease history or treatment within 6 months before the first dose (including but not limited to stroke, , acute myocardial infarction, unstable angina, coronary artery bypass graft surgery, percutaneous coronary intervention [excluding diagnostic angiography], severe arrhythmia).
  7. At screening, cardiac disease with 12-lead indicating the presence of sinus or atrioventricular block, or the Investigator believes that the ECG abnormality at screening will interfere with the interpretation of ECG results during subsequent follow-up, especially excluding > 450 ms (male) and QTcF > 470 ms (female).
  8. Presence of poorly controlled hypertension.
  9. Presence at screening in either ear of an abnormal baseline PTA audiometry assessment. History of tinnitus requiring medical intervention prior or during screening or other significant ear diseases.
  10. -proven or clinically suspected inflammatory bowel disease (eg, diarrhea with or without blood or rectal bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or incontinence for more than 4 weeks without a confirmed alternative diagnosis or endoscopic or radiologic evidence of enteritis/colitis without a confirmed alternative diagnosis).
  11. Positive for serum virological tests, defined as: positive antibody; positive with HBV-DNA > ; or positive antibody with HCV-RNA > ULN.
  12. Active syphilis, defined as a positive treponema pallidum-specific antibodies test (TPPA or FTA-ABS) and a consultation with an infectious disease specialist confirming the need for anti-syphilis treatment.
  13. Active tuberculosis, defined as a positive interferon-gamma release assay (IGRA or T-SPOT) for mycobacterium tuberculosis infection and a consultation with an infectious disease specialist confirming the need for anti- tuberculosis treatment.
  14. Active bacterial or fungal infection requiring systemic treatment within 7 days before the first administration.
  15. Participants who received or plan to receive live or attenuated within 4 weeks before the first dose or during the study period.
  16. Participants who underwent major surgery within 4 weeks before the first dose or are expected to undergo surgery during the study period or within 4 weeks after the study.
  17. Known to any of the components of MHB018A or prior hypersensitivity reactions to monoclonal antibodies.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    MHB018A

    Patients with TED will be randomized to receive 6 subcutaneous injections of either MHB018A (450mg) or MHB018A placebo, once every 4 weeks (q4w)

    Drug: MHB018A

  • Placebo comparator
    MHB018A Placebo

    Patients with TED will be randomized to receive 6 subcutaneous injections of either MHB018A (450mg) or MHB018A placebo, once every 4 weeks (q4w)

    Drug: MHB018A placebo

Interventions

  • MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)

  • DrugMHB018A placebo

    6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)

06

What researchers measure

Primary outcomes

  1. Proptosis response rate at Week 24

    The percentage of subjects with a reduction in proptosis of ≥2 mm in the study eye/target eye compared to baseline, without deterioration (≥2 mm) in the fellow eye.

    Time frame: Week 24

Secondary outcomes

  1. Overall response rate

    The percentage of subjects with ≥2-points in Clinical Activity Score (CAS) reduction and ≥2 mm reduction in proptosis from baseline, provided there is no corresponding deterioration (≥2-points/mm increase) in CAS or proptosis in the fellow eye.

    Time frame: Week 24

  2. Change in proptosis

    Change from baseline in proptosis in the study eye as measured by exophthalmometer at Week 24

    Time frame: Baseline, up to Week 24

  3. Percentage of subjects with CAS of 0 or 1

    The percentage of subjects with a CAS (Clinical Activity Score) of 0 or 1 in the study eye/target eye. CAS ranges from 0 to 7, while higher scores mean a worse outcome.

    Time frame: Week 24

  4. Change in CAS

    The mean change from baseline to Week 24 in the CAS (Clinical Activity Score) in the study eye/target eye. CAS ranges from 0 to 7, while higher scores mean worse outcome.

    Time frame: Week 24

  5. Diplopia response rate

    The percentage of subjects with a reduction in diplopia severity by ≥1 grade.

    Time frame: Week 24

  6. Change in Quality of Life (GO-QOL) Scores

    The mean change in scores from the Graves' Ophthalmopathy Quality of Life questionnaire compared to baseline. The GO-QoL is a self-filled questionnaire containing 16 items. The raw scores for items 1-8 and items 9-16 are summed separately, each yielding a total raw score ranging from 8 to 24. Each raw score is then transformed into a 0-100 scale using the following formula: Total Score = (Raw Score - 8) ÷ 16 × 100. Higher scores indicate better quality of life.

    Time frame: Week 24

  7. Pharmacokinetic Parameter Trough Concentration for MHB018A

    Trough concentration (Ctrough) will be assessed using non-compartmental methods in participants randomized to the MHB018A group.

    Time frame: Up to Week 24

  8. Anti-MHB018A antibody (ADA) incidence

    The percentage of subjects developing anti-MHB018A antibodies.

    Time frame: Up to Week 24 and at end-of-trial (EOT) visit

07

Study locations

1 of 1 sites recruiting
  • Hype Clinical Research
    Coral Gables, Florida 33134, United States
    Recruiting
    • Hype Clinical Research · Contact(786) 471-1922
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's planned 22 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Sep 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2026
First posted
Jun 2, 2026
StartActual
Sep 28, 2026was Dec 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 14, 2026
Sites
1 site added — first site in United States
Show site
  • Hype Clinical Research · Coral Gables, United States
Oct 14, 2026
Start date
Dec 2026→Sep 28, 2026 (actual)
Oct 14, 2026
Eligibility
4 inclusion criteria edited, 1 added, 5 removed; 4 exclusion criteria edited, 13 added, 19 removed
What changed in the criteria
Inclusion criteria
  • RemovedSubjects voluntarily participating in the study and signing the informed consent form;
  • RemovedAged 18-75 years (inclusive), of any gender;
  • AddedBody weight ≤ 120 kg.
  • EditedClinical diagnosis of active Thyriod Eye Disease (TED)TED with documented medical evidence of symptoms and signs in the study eye occurring within the 12 months prior to study screening. The Clinical Activity Score (CAS) of the study eye/target eye at screening and baseline must be ≥ 3 points (7-point scale).
  • EditedSubjects with a clinicalClinical diagnosis of moderate -to -severe TED at screening and baseline.
  • EditedDoesDo not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study.
  • EditedDiabetic subjectsparticipants must have well-controlled stable disease.
  • RemovedSufficient bone marrow and organ function.
  • RemovedEligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding.
  • RemovedSubject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.
Exclusion criteria
  • RemovedDecreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement.
  • RemovedCorneal decompensation unresponsive to medical management.
  • RemovedDecrease in CAS of ≥ 2 points or decrease in proptosis of ≥ 2 mm between screening and baseline.
  • RemovedFree thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal reference range at screening.
  • RemovedSubjects who have previously received orbital radiotherapy or ophthalmic surgery for TED.
  • RemovedSubjects who received oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks before the first dose; subjects who received periorbital/orbital steroid injections within 3 months before the first dose.
  • RemovedSubjects who used oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to Screening, excluding local use (topical, nasal, inhalation).
  • RemovedAny previous treatment with rituximab, tocilizumab, other immunosuppressive agent use within 3 months prior to Screening.
  • RemovedPrevious treatment targeting IGF-1R.
  • RemovedSelenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during the trial; however, taking a multivitamin that includes selenium and/or biotin is allowed.
  • RemovedUse of an investigational agent for any condition within 30 days prior to Screening or anticipated use during the course of the trial.
  • AddedParticipants who have: a compressive optic neuropathy of TED that requires timely and effective medical intervention; corneal abnormalities that may compromise the assessment of efficacy; previously received orbital radiotherapy or ophthalmic surgery for TED.
  • AddedParticipants who received: oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks prior to the first dose of study intervention; periorbital or intraorbital steroid within 3 months before the first dose of study intervention; oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to the first dose of study intervention, excluding local use (topical, nasal, inhalation); other immunosuppressive agent, including treatment with any anti-CD20 monoclonal antibody (eg, rituximab) within 6 months before the first dose of study intervention; or treatment with any other immunosuppressive agent (eg, tocilizumab) within 3 months before the first dose of study intervention; or receipt of periorbital or intraorbital administration of any such immunosuppressive agent at any time (eye drops or ointments for dry eye are permitted); previous treatment targeting IGF-1R.
  • AddedHave received: selenium and vitamin D supplements (as single agents) within 2 weeks prior to the first dose of study intervention or during the study (non-prescription multivitamin containing them is permitted), radioactive iodine treatment within 8 weeks prior to the first dose of study intervention; periocular botulinum toxin injection within 12 months prior to the first dose of study intervention; an investigational agent for any condition (including TED) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  • EditedIdentified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude study participation or complicate interpretation of the study results.
  • RemovedMalignant condition in the past 5 years before signing the ICF (except successfully treated basal/squamous cell carcinoma of the skin).
  • RemovedAcute cardiovascular disease history or treatment within 6 months before the first dose.
  • RemovedPresence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis.
  • RemovedPregnant or lactating women.
  • RemovedDrug or alcohol abuse during the screening period.
  • RemovedHearing impairment history in either ear during the screening period; or abnormal pure tone audiometry results.
  • RemovedBiopsy-proven or clinically suspected inflammatory bowel disease.
  • RemovedPositive results for serum virology tests (defined as pos
  • AddedAny malignancy within 5 years prior to the first dose of study intervention, with the exception of successfully treated malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin or carcinoma of the thyroid.
  • AddedAcute cardiovascular disease history or treatment within 6 months before the first dose (including but not limited to stroke, transient ischemic attack, acute myocardial infarction, unstable angina, coronary artery bypass graft surgery, percutaneous coronary intervention [excluding diagnostic angiography], severe arrhythmia).
  • AddedAt screening, cardiac disease with 12-lead ECG indicating the presence of sinus or atrioventricular block, or the Investigator believes that the ECG abnormality at screening will interfere with the interpretation of ECG results during subsequent follow-up, especially excluding QTcF > 450 ms (male) and QTcF > 470 ms (female).
  • AddedPresence of poorly controlled hypertension.
  • AddedPresence at screening in either ear of an abnormal baseline PTA audiometry assessment. History of tinnitus requiring medical intervention prior or during screening or other significant ear diseases.
  • AddedBiopsy-proven or clinically suspected inflammatory bowel disease (eg, diarrhea with or without blood or rectal bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or incontinence for more than 4 weeks without a confirmed alternative diagnosis or endoscopic or radiologic evidence of enteritis/colitis without a confirmed alternative diagnosis).
  • AddedPositive for serum virological tests, defined as: positive HIV antibody; positive HBsAg with HBV-DNA > ULN; or positive HCV antibody with HCV-RNA > ULN.

…and 6 more changes, on the record history on ClinicalTrials.gov ↗

Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Hype Clinical Research · Coral Gables, United States
    Start date Dec 2026→Sep 28, 2026 (now actual)
    Eligibility 4 inclusion criteria edited, 1 added, 5 removed; 4 exclusion criteria edited, 13 added, 19 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedSubjects voluntarily participating in the study and signing the informed consent form;
    • RemovedAged 18-75 years (inclusive), of any gender;
    • AddedBody weight ≤ 120 kg.
    • EditedClinical diagnosis of active Thyriod Eye Disease (TED)TED with documented medical evidence of symptoms and signs in the study eye occurring within the 12 months prior to study screening. The Clinical Activity Score (CAS) of the study eye/target eye at screening and baseline must be ≥ 3 points (7-point scale).
    • EditedSubjects with a clinicalClinical diagnosis of moderate -to -severe TED at screening and baseline.
    • EditedDoesDo not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study.
    • EditedDiabetic subjectsparticipants must have well-controlled stable disease.
    • RemovedSufficient bone marrow and organ function.
    • RemovedEligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding.
    • RemovedSubject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.
    Exclusion criteria
    • RemovedDecreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement.
    • RemovedCorneal decompensation unresponsive to medical management.
    • RemovedDecrease in CAS of ≥ 2 points or decrease in proptosis of ≥ 2 mm between screening and baseline.
    • RemovedFree thyroxine (FT4) and free triiodothyronine (FT3) levels <50% above or below the normal reference range at screening.
    • RemovedSubjects who have previously received orbital radiotherapy or ophthalmic surgery for TED.
    • RemovedSubjects who received oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks before the first dose; subjects who received periorbital/orbital steroid injections within 3 months before the first dose.
    • RemovedSubjects who used oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to Screening, excluding local use (topical, nasal, inhalation).
    • RemovedAny previous treatment with rituximab, tocilizumab, other immunosuppressive agent use within 3 months prior to Screening.
    • RemovedPrevious treatment targeting IGF-1R.
    • RemovedSelenium and biotin must be discontinued 3 weeks prior to Screening and must not be restarted during the trial; however, taking a multivitamin that includes selenium and/or biotin is allowed.
    • RemovedUse of an investigational agent for any condition within 30 days prior to Screening or anticipated use during the course of the trial.
    • AddedParticipants who have: a compressive optic neuropathy of TED that requires timely and effective medical intervention; corneal abnormalities that may compromise the assessment of efficacy; previously received orbital radiotherapy or ophthalmic surgery for TED.
    • AddedParticipants who received: oral or intravenous corticosteroids or corticosteroid eye drops/ointments for TED within 4 weeks prior to the first dose of study intervention; periorbital or intraorbital steroid within 3 months before the first dose of study intervention; oral or intravenous corticosteroids for reasons other than TED within 4 weeks prior to the first dose of study intervention, excluding local use (topical, nasal, inhalation); other immunosuppressive agent, including treatment with any anti-CD20 monoclonal antibody (eg, rituximab) within 6 months before the first dose of study intervention; or treatment with any other immunosuppressive agent (eg, tocilizumab) within 3 months before the first dose of study intervention; or receipt of periorbital or intraorbital administration of any such immunosuppressive agent at any time (eye drops or ointments for dry eye are permitted); previous treatment targeting IGF-1R.
    • AddedHave received: selenium and vitamin D supplements (as single agents) within 2 weeks prior to the first dose of study intervention or during the study (non-prescription multivitamin containing them is permitted), radioactive iodine treatment within 8 weeks prior to the first dose of study intervention; periocular botulinum toxin injection within 12 months prior to the first dose of study intervention; an investigational agent for any condition (including TED) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
    • EditedIdentified pre-existing ophthalmic disease that, in the judgment of the Investigator, would preclude study participation or complicate interpretation of the study results.
    • RemovedMalignant condition in the past 5 years before signing the ICF (except successfully treated basal/squamous cell carcinoma of the skin).
    • RemovedAcute cardiovascular disease history or treatment within 6 months before the first dose.
    • RemovedPresence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis.
    • RemovedPregnant or lactating women.
    • RemovedDrug or alcohol abuse during the screening period.
    • RemovedHearing impairment history in either ear during the screening period; or abnormal pure tone audiometry results.
    • RemovedBiopsy-proven or clinically suspected inflammatory bowel disease.
    • RemovedPositive results for serum virology tests (defined as pos
    • AddedAny malignancy within 5 years prior to the first dose of study intervention, with the exception of successfully treated malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin or carcinoma of the thyroid.
    • AddedAcute cardiovascular disease history or treatment within 6 months before the first dose (including but not limited to stroke, transient ischemic attack, acute myocardial infarction, unstable angina, coronary artery bypass graft surgery, percutaneous coronary intervention [excluding diagnostic angiography], severe arrhythmia).
    • AddedAt screening, cardiac disease with 12-lead ECG indicating the presence of sinus or atrioventricular block, or the Investigator believes that the ECG abnormality at screening will interfere with the interpretation of ECG results during subsequent follow-up, especially excluding QTcF > 450 ms (male) and QTcF > 470 ms (female).
    • AddedPresence of poorly controlled hypertension.
    • AddedPresence at screening in either ear of an abnormal baseline PTA audiometry assessment. History of tinnitus requiring medical intervention prior or during screening or other significant ear diseases.
    • AddedBiopsy-proven or clinically suspected inflammatory bowel disease (eg, diarrhea with or without blood or rectal bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or incontinence for more than 4 weeks without a confirmed alternative diagnosis or endoscopic or radiologic evidence of enteritis/colitis without a confirmed alternative diagnosis).
    • AddedPositive for serum virological tests, defined as: positive HIV antibody; positive HBsAg with HBV-DNA > ULN; or positive HCV antibody with HCV-RNA > ULN.

    …and 6 more changes, on the record history on ClinicalTrials.gov ↗

    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07622108
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Sep 28, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

CMO/ Senior Vice President of R&D
Contact
jwshi@minghuipharma.com
86 0571-86963293

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MHB018A

Start the discussion